Colorectal Cancer (CRC) is a major public health problem and is the fourth leading cause of cancer death worldwide. It is the third most common cancer among men and the second most common in women. The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.

Over half of the incident cases of colorectal cancer (CRC) are diagnosed in patients over the age of 50. The percentage of people over 50 in 2017 and 2015 was 46.3% and 45.5% in Japan; 30.2% and 28.5% in China; 18.7% and 18% in India; 34.4% and 33.8% in Australia; and 36.4% and 34.7% in South Korea.

"Growing awareness of the disease and associated risk factors together with the availability of free testing services for CRC patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly."

Key Highlights:

• Aging Population to Increase Disease Prevalence
  
• Immune Checkpoint Inhibitors Set to Have a Significant Impact on the CRC Market
  
• Biomarker-Driven Strategies to Add Complexity to the CRC Treatment Algorithm
  
• Increasing Diagnosis of Mutation Status and Early Diagnosis
  
• Roche’s Avastin to Remain the Leader of the CRC Space despite the Launch of Bevacizumab Biosimilars
  
• High Unmet Need Remains for Neoadjuvant/Adjuvant Treatments to Improve Cure Rates in Early-Stage Resectable CRC Patients